Diplomat to Exclusively Dispense Taro Drug KEVEYIS™
FLINT, Mich. – August 13, 2015 – The nation’s largest independent specialty pharmacy has been named the exclusive distributor for Taro’s primary hyperkalemic and hypokalemic periodic paralysis treatment, KEVEYIS™ (dichlorphenamide).
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it will be the sole distributor of KEVEYIS™ (dichlorphenamide), recently approved for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.
KEVEYIS™ is the first medicine approved by the FDA for the treatment of primary periodic paralysis, which is estimated to affect approximately 5,000 people in the United States.
“We are excited to be a sole distributor of KEVEYIS™ and give patients a therapy option for primary hyperkalemic and hypokalemic periodic paralysis,” said Gary Kadlec, president of Diplomat. “The FDA approval of KEVEYIS™ is an important advancement in the treatment of hyperkalemic and hypokalemic periodic paralysis, and we are proud to be able to support these patients and their caregivers.”
Taro has created the Keys2Care program, which will provide a suite of patient support services to ensure people diagnosed with periodic paralysis can receive treatment with KEVEYIS™ as soon as possible. As part of this program, Diplomat is working with Taro to offer access and support to patients who are prescribed KEVEYIS™ and their caregivers.
KEVEYIS™ is expected to be available in the third quarter. To be notified when KEVEYIS™ becomes available, enroll at www.keveyis.com. Please see full prescribing information at http://www.keveyis.com/FINAL%20Approved%20Keveyis%20PI_%208.7.15.pdf.
To learn more about Diplomat, visit www.diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | firstname.lastname@example.org
Gary Rice, RPh, MS, MBA, CSP,
Vice President, Clinical Services
810.768.9863 | email@example.com